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Abstract
Background: A wide range of possible malaria vaccines is being considered and there is a need to identify
which vaccines should be prioritized for clinical development. An important element of the information
needed for this prioritization is a prediction of the cost-effectiveness of potential vaccines in the
transmission settings in which they are likely to be deployed. This analysis needs to consider a range of
delivery modalities to ensure that clinical development plans can be aligned with the most appropriate
deployment strategies.
Methods: The simulations are based on a previously published individual-based stochastic model for the
natural history and epidemiology of Plasmodium falciparum malaria. Three different vaccine types: pre-
erythrocytic vaccines (PEV), blood stage vaccines (BSV), mosquito-stage transmission-blocking vaccines
(MSTBV), and combinations of these, are considered each delivered via a range of delivery modalities
(Expanded Programme of Immunization – EPI-, EPI with booster, and mass vaccination combined with EPI).
The cost-effectiveness ratios presented are calculated for four health outcomes, for assumed vaccine
prices of US$ 2 or US$ 10 per dose, projected over a 10-year period.
Results: The simulations suggest that PEV will be more cost-effective in low transmission settings, while
BSV at higher transmission settings. Combinations of BSV and PEV are more efficient than PEV, especially
in moderate to high transmission settings, while compared to BSV they are more cost-effective in
moderate to low transmission settings. Combinations of MSTBV and PEV or PEV and BSV improve the
effectiveness and the cost-effectiveness compared to PEV and BSV alone only when applied with EPI and
mass vaccinations. Adding booster doses to the EPI is unlikely to be a cost-effective alternative to
delivering vaccines via the EPI for any vaccine, while mass vaccination improves effectiveness, especially in
low transmission settings, and is often a more efficient alternative to the EPI. However, the costs of
increasing the coverage of mass vaccination over 50% often exceed the benefits.
Conclusion: The simulations indicate malaria vaccines might be efficient malaria control interventions,
and that both transmission setting and vaccine delivery modality are important to their cost-effectiveness.
Alternative vaccine delivery modalities to the EPI may be more efficient than the EPI. Mass vaccination is
predicted to provide substantial health benefits at low additional costs, although achieving high coverage
rates can lead to substantial incremental costs.
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Background
Plasmodium falciparum malaria represents one of the
world's major causes of morbidity and mortality[1,2] and
there is a pressing need for new effective interventions,
which, combined with the existing strategies, could effec-
tively reduce the burden of malaria in endemic areas[3].
Among these potential new interventions are vaccines
and, although there is currently no licensed malaria vac-
cine, a number of candidates are under development. The
complexity of the malaria life cycle means that a number
of different stages of the parasite can be targeted. The can-
didate that is most advanced in clinical development[4,5]
targets pre-erythrocytic stages of the parasite.
Appraisals of candidate malaria vaccines should not
include only efficacy and effectiveness evaluations but
also cost effectiveness analyses (CEA) aimed at guiding
vaccine developers, funding agencies[6], and policy mak-
ers to allocate resources so that social and economic ben-
efits are maximized[7,8]. CEA can help in evaluating
alternative health interventions because health decision
makers are primarily interested in knowing what health
improvements can be bought with a given budget, and
not the overall economic impact per se[9,10]. Previously,
the likely epidemiological effects[11] and cost-effective-
ness[12] of pre-erythrocytic vaccines when delivered in
areas of stable endemic malaria via the Expanded Pro-
gramme on Immunization (EPI) were estimated based on
a dynamic model of malaria epidemiology[13]. These
simulations showed that at moderate vaccine prices the
cost-effectiveness of such vaccines may be similar to that
of other preventive and curative interventions against
malaria. However, more evidence is needed on the likely
cost-effectiveness of different malaria vaccines under
development, and on the implications for it of adopting
alternative means of deployment. The cost-effectiveness
of a malaria vaccine will depend not only on the vaccine
profile and the transmission setting, but also on the vacci-
nation coverage that can be achieved, on the vaccine deliv-
ery costs, and of the operational feasibility of the delivery
modalities adopted to deploy it.
A companion article to the present one[14], reports on the
simulations of the likely epidemiological effects of three
different malaria vaccine types: pre-erythrocytic vaccines
(PEV), blood stage vaccines (BSV), mosquito-stage trans-
mission-blocking vaccines (MSTBV), and combinations
of these. A range of different delivery modalities (EPI, EPI
with booster, and mass vaccination combined with EPI)
were considered. In this article, both the health system
and vaccine delivery costs are attached to the events
recorded in these simulations to calculate cost-effective-
ness ratios for each deployment strategy and each vaccine,
and for each of four health outcomes over a 10-year time-
horizon.
Methods
Perspective and boundary
The simulations refer to CEA under the perspective of the
society as a whole, although only direct costs are included.
They thus consider all relevant direct resource inputs and
costs to the interventions, and resource consequences,
costs, and health impacts resulting from the interventions.
The indirect economic impact of malaria such as potential
earning forgone of patients and unpaid carers is not
included, as its inclusion is controversial in CEA[15,16].
The CEA follows standard cost-effectiveness methodol-
ogy[8,17-21].
Interventions being compared
The simulations of vaccines are based on a previously
described model for the natural history and epidemiology
of P. falciparum malaria[13]. This model uses an underly-
ing model based on descriptions of the course of parasite
densities in malaria therapy patients[22]. The parameteri-
zation of the model for the present simulations is
described in the companion article[14] and reviewed in
more detail elsewhere[23]. Briefly, each simulated vaccine
is characterized by an average initial efficacy (the efficacy
reached after completion of a schedule of three doses),
and by a half-life of this efficacy, which is assumed to
decay exponentially with time. The vaccinated population
is assumed to be heterogeneous in the response to vacci-
nation, and to allow for this we assign initial values for
efficacy drawn from a beta-distribution[11] (simulated
vaccines are delivered at specified ages, and a range of cov-
erage values is considered for vaccination to allow for
individuals who do not complete the full schedule).
The effects of the three different vaccine types and four
combinations were modeled as follows (see also [14]):
(i) Pre-erythrocytic vaccines (PEV)
Pre-erythrocytic vaccines are assumed to lead to a reduc-
tion in the proportion of inoculations from the bites of
infected mosquitoes that lead to blood stage infection and
the vaccine efficacy is assumed to be equal to the propor-
tion by which this force of infection is reduced.
(ii) Blood stage vaccines (BSV)
A blood stage vaccine is assumed to reduce parasite densi-
ties at each time step by a proportion equal to the vaccine
efficacy.
(iii) Mosquito stage transmission blocking vaccines (TBV)
Vaccine efficacy is equivalent to the proportional reduc-
tion of the probability that a mosquito becomes infected
from any one feed on an infectious vaccinated human.Malaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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(iv) Combination vaccines
Combination vaccines of PEV with TBV, BSV with TBV,
BSV with PEV and also a three-way combination of PEV
with both BSV and MSTBV are considered. For each com-
bination, PEV and BSV are assumed to be matched in both
the initial efficacy and in their rate of decay. Only combi-
nations of PEV, BSV and of PEV-BSV with high efficacy
MSTBV are considered since it is unlikely that a MSTBV
with low efficacy would be developed.
Vaccine delivery modalities
The delivery of the three vaccine types and their combina-
tions through the following three strategies are simulated:
(i) EPI
Delivery of the vaccines through the EPI according to the
usual diphtheria tetanus pertussis (DTP3) vaccine sched-
ule: age 1, 2 and 3 months.
(ii) EPI with booster
In addition to the above EPI schedule, this modality
includes booster doses at 1, 2, 3 and 4 years after the last
EPI schedule. The effect of a booster dose is to restore the
protective efficacy to the level achieved after the third dose
in the same individual.
(iii) Mass vaccination combined with EPI
Delivery via EPI to infants is supplemented with a mass
vaccination campaign at the beginning of the intervention
period and additional campaigns after five years.
Vaccine coverage
For vaccines delivered via EPI, the assumed coverage of
full vaccination (three doses) corresponds to that reported
in Tanzania for three doses of diphtheria tetanus pertus-
sis-hepatitis B virus vaccine in the year 2003, which stood
at 89%. The assumed dropout rate from the first to the
third dose is 6% since coverage for the first dose of DTP-
HBV vaccine was 95%. When booster doses are included,
it is assumed that 99% of those that receive the third EPI
dose will be given a booster dose 1, 2, 3 and 4 years after
the last EPI dose. For mass vaccination the coverage levels
of 30, 50 and 70% are simulated.
Case management model
As detailed in the companion article[14], the simulations
of the effects of vaccine interventions use a case manage-
ment model including both formal and informal treat-
ment, similar to a previous study of the authors[24]. An
artemisinin-based combination therapy (ACT), arte-
mether-lumefantrine, is used as first line treatment for
uncomplicated malaria, as per recent policy changes, and
the drug action model was modified accordingly, both in
terms of the potential to reduce rates of severe disease,
sequelae and death, and the impact on transmission
intensity. The model assumes that 90% of patients com-
ply with the ACT treatment schedule and have a cure rate
of 85%, while in non-compliers there is no effect.
Measurement of health impact
The effect of vaccines is evaluated by simulating the
malaria dynamics in a population of 100,000 people over
a 10-year time horizon. For each of the seven vaccine
options, and each delivery modality, the simulations start
from a reference set of assumptions (Table 1 of the com-
panion article[14]). Each of the 21 vaccine schemes is
compared with the reference situation at six different
transmission intensities to obtain cost effectiveness results
for each of the 126 vaccine scenarios in preventing the fol-
lowing outcomes: uncomplicated episodes, severe epi-
sodes, deaths and DALYs.
Each simulation is repeated three times using different
seeds to initialize the random number generator, and each
of these simulations is compared with an independent
simulation of a reference scenario: a control population
with no vaccine, but with the same human demography,
baseline transmission, and health system.
To estimate the number of disability adjusted life years
(DALYs), years of life lived with disability are calculated
on the basis of the duration of disability, and respective
disability weights. Weights for different malaria attributa-
ble disease conditions have been obtained from the Glo-
bal Burden of Disease (GBD) study[25]. DALYs are
computed with no age weighting to follow standard cost-
effectiveness practices[26]. The disability associated with
anemia is assigned to the same time period as the malaria
infections causing it.
Years of life lost (YLLs) and DALYs are calculated assum-
ing age-specific life expectancies based on the life-table
from Butajira, Ethiopia, with an average life expectancy of
46.6 years at birth[27]. This life-table represents that of an
East African setting with low malaria transmission and is
very similar to that for Hai District, a high altitude and
low malaria prevalence site in Tanzania[28]. YLLs for each
simulated death are computed under the assumption that
this life table would apply in the absence of malaria.
Vaccine delivery costs
The vaccine delivery costs are estimated using the method-
ology of a previous study by the authors[29], which was
based on an ingredient approach requiring information
on the quantities of physical inputs needed and their unit
costs. The costs of introducing a malaria vaccine into the
EPI in Tanzania include those related to an assumed range
of vaccine purchase costs, and data collected from Tanza-
nia on costs of distribution, cold chain, management, vac-
cine delivery by health facilities, training, and socialMalaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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mobilization[30] (Table 1). For booster doses, the per-
dose delivery cost is assumed to be the same as that of rou-
tine EPI.
The costs of vaccine campaigns are estimated by adding to
the purchase costs, those costs associated with distribu-
tion, cold chain, management, specific programme activi-
ties, personnel, and other capital costs, estimated by a
study in Tanzania on a campaign for Vitamin A supple-
mentation[31] (Table 2).
Potential cost savings of the interventions
The costs of treating those seeking health care for malaria
episodes are calculated under the reference and the vac-
cine scenarios modeled. This allows calculation of
expected cost savings associated with the introduction of
an efficacious malaria vaccine. The case management cost
inputs correspond to those published previously by the
authors adjusted for inflation to 2007[24,32-36] (Table 3)
and the first line treatment for uncomplicated malaria
changed to an ACT (artemether/lumefantrine), for which
Table 1: Vaccine delivery costs – routine EPI – US$ 2006
Item Source Costs (US$)
Net vacc. purchase cost per dose Derived 1.23 2.45 12.25
Vaccine price per dose 1 2 10
Freight UNICEF estimates 0.0417 0.0417 0.0417
Wastage WHO estimates 15% 15% 15%
Distribution per dose [29] 0.09 0.09 0.09
Storage per dose [29] 0.03 0.03 0.03
Management per dose [29] 0.003 0.003 0.003
Delivery per dose Derived 0.13 0.13 0.13
Syringes 0.06 0.06 0.06
Unit cost per dose [30] 0.05 0.05 0.05
Freight UNICEF estimates 0.0417 0.0417 0.0417
Wastage WHO estimates 10% 10% 10%
Safety boxes 0.01 0.01 0.01
Unit cost per dose [30] 0.0122 0.0122 0.0122
Freight UNICEF estimates 0.0417 0.0417 0.0417
Wastage WHO estimates 10% 10% 10%
Personnel facility level [29] 0.06 0.06 0.06
Waste management
Training over 5 years) [29] 0.03 0.03 0.03
Social mobilization (av) [29] 0.12 0.12 0.12
TOTAL COST PER DOSE Derived 1.63 2.86 12.66
*adjusted for inflationMalaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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Table 2: Vaccine delivery costs – Campaign – US$ 2006
Item Source Costs (US$)
Net vacc. purchase cost per dose Derived 1.23 2.45 12.25
Vaccine price per dose 1 2 10
Freight UNICEF estimates 0.0417 0.0417 0.0417
Wastage WHO estimates 15% 15% 15%
Distribution per dose [29] 0.09 0.09 0.09
Storage per dose [29] 0.03 0.03 0.03
Management per dose [29] 0.003 0.003 0.003
Delivery per dose Derived 0.07 0.07 0.07
Syringes 0.06 0.06 0.06
Unit cost per dose [30] 0.05 0.05 0.05
Freight UNICEF estimates 0.0417 0.0417 0.0417
Wastage WHO estimates 10% 10% 10%
Safety boxes 0.01 0.01 0.01
Unit cost per dose [30] 0.0122 0.0122 0.0122
Freight UNICEF estimates 0.0417 0.0417 0.0417
Wastage WHO estimates 10% 10% 10%
Programme-specific costs 0.07 0.07 0.07
Allowances [31] 0.1132 0.1132 0.1132
Fuel & Maintenance 0.0337 0.0337 0.0337
Fax & Telephone 0.0094 0.0094 0.0094
Refreshments 0.0058 0.0058 0.0058
Stationary & Postage 0.0056 0.0056 0.0056
Photocoping 0.0051 0.0051 0.0051
Transport 0.0050 0.0050 0.0050
Social mobilization 0.0048 0.0048 0.0048
Other 0.0005 0.0005 0.0005
Personnel cost 0.42 0.42 0.42
Government 0.3017 0.3017 0.3017
Non Government 0.1141 0.1141 0.1141Malaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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the public sector price posted by WHO was used (Table
4).
The numbers of uncomplicated and severe malaria epi-
sodes averted due to vaccination are multiplied by the
case management unit costs, as described above, to esti-
mate the potential cost savings for both the health system
and households. The cost savings are subtracted from the
vaccine costs to compute the net costs of the interven-
tions.
Calculating cost-effectiveness ratios and interpreting the 
results
The cost-effectiveness ratios presented are calculated for
four health outcomes: uncomplicated and severe malaria
episodes averted, DALYs averted, and deaths averted.
Future costs and benefits are discounted at 3%. The cost-
effectiveness ratios are presented for assumed vaccine
prices of US$ 2 or US$ 10 per dose for all the vaccines and
vaccine combinations. The results are presented as cost-
effectiveness on a 10-year period.
The cost-effectiveness ratios are to be interpreted as incre-
mental cost-effectiveness ratios of implementing the inter-
ventions in the simulated scenarios relative to a do-
nothing scenario, which corresponds to maintaining only
the case management model described above.
Accounting for uncertainty
The cost-effectiveness results are based on an advanced
modeling methodology aimed at representing reality as
accurately as possible. The large number of scenarios sim-
ulated includes some sensitivity analyses of results for key
variables, for instance for vaccine efficacy levels. The likely
impact on results of other key features of potential malaria
vaccines is explored in the companion article[14].
However, many sources of uncertainty cannot be captured
by these sensitivity analyses. Probabilistic sensitivity anal-
ysis and expected value of information analysis could
serve to further assess the impact of uncertainty on the
simulation results [37-40], but there are technical prob-
lems in implementing and presenting such analyses for a
large set of interventions and scenarios. It has been, there-
fore, planned to run an expected value of information
analysis on a sub-set of simulations that will be reported
in another article.
Results
Pre-erythrocytic vaccines
At a reference transmission setting with annual entomo-
logical inoculation rate (EIR) of 21, the simulations pre-
dict that a PEV with 52% initial efficacy could be very cost-
effective when delivered via EPI alone. At a vaccine price
of US$2 per dose, the cost per uncomplicated malaria epi-
sode averted would be around US$ 5, the cost per severe
malaria episode averted US$ 269, the cost per DALY
averted around US$ 35 and the cost per death averted
US$1057 (see table S1 and S2, Additional file 1). The cost-
effectiveness ratios are lower for higher effectiveness levels
(Figure 1). They increase almost proportionally with vac-
cine price reaching US$ 160 per DALY averted and US$
4869 per death averted for a vaccine price of US$ 10 per
dose (see table S3 and S4, Additional file 1).
The proportion of events averted by PEV delivered via EPI
with booster doses is slightly higher, but the cost per
uncomplicated episode averted is 20% higher (see table
S1, Additional file 1), and cost per DALY and death
averted is around 31% higher (see table S2, Additional file
1).
With EPI and mass vaccination the proportion of events
averted is 5% higher for mass vaccination coverage of 50%
and 8% higher for coverage of 70%[14], and the cost per
uncomplicated episode averted is slightly lower. How-
ever, the costs per DALY and death averted are around
60%–66% higher (see table S1 and S2, Additional file 1).
For higher efficacy levels the pattern is similar, showing
that the incremental benefits of these deployment modal-
ities, in this transmission setting, are modest (Figure 1).
In low transmission settings, while the cost per uncompli-
cated episode averted under EPI alone is similar to that in
the reference transmission setting (see table S1 and S2,
Additional file 1), the cost per DALY and death averted are
Capital cost 0.07 0.07 0.07
Vehicles 0.0410 0.0410 0.0410
Social mobilization 0.0156 0.0156 0.0156
Long term training & studies 0.0153 0.0153 0.0153
Other 0.0017 0.0017 0.0017
TOTAL COST PER DOSE Derived 1.98 3.20 13.01
*adjusted for inflation
Table 2: Vaccine delivery costs – Campaign – US$ 2006 (Continued)Malaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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Table 3: Case management unit costs US$ 2006
Costs (US$) Source
Household average out of pocket costs per outpatient visit
Travel costs 0.09 [32]
Medical supplies 0.03 [32]
Non medical supplies 0.22 [32]
Travel costs 0.09 [32]
Unit cost of outpatient visit 0.7176 derived
% of outpatient visits that take place at health centers 17% [33]
% of outpatient visits that take place at dispensaries 72% [33]
% of outpatient visits that take place at hospitals 10% [33]
cost per outpatient visits at health centers 1.47 derived
cost per outpatient visits at dispensaries 1.18 derived
cost per outpatient visits at hospitals 2.54 derived
% of patients using Diagnostic Techniques 0.1 [34]
unit cost of Diagnostic Technique 0.3 [34]
% of outpatient visit cost that are recurrent 69% [32]
% of outpatient visit cost that are fixed 0.25 [32]
Hospital costs of severe episodes
Non drug cost per admission when patient fully recorvers 14.4 derived
Non drug cost per admission when patient recorvers with NS 32 derived
Non drug cost per admission when patient dies 6.4 derived
Non drug cost per day of stay 9.00 [36]
Capital 2.60
Recurrent 6.40
average length of stay when patient fully recovers 4.5 [41]
average length of stay when patient recovers with NS 10 [41]Malaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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lower at US$ 31 per DALY averted and US$ 925 per death
averted at a vaccine price of US$ 2 per dose (see table S2
and S4, Additional file 1). Adding booster doses leads to
higher cost-effectiveness ratios for efficacy levels up to
around 60%, but at near 100% efficacy the cost-effective-
ness ratios become similar (Figure 1). In contrast, when
mass vaccination is added to EPI, the cost-effectiveness
ratios decrease substantially, by around 70% for the cost
per uncomplicated case averted (see table S1 and S3,
Additional file 1), and by 24% to 28% for the cost per
DALY and death averted (see table S2 and S4, Additional
file 1).
In high transmission settings, the effectiveness of PEV is
low[14] and the cost-effectiveness ratios are therefore
higher than in the other transmission settings irrespective
of delivery modality. For some outcomes, vaccination
even leads to an increase in the number of clinical
events[14], and, therefore, to negative cost-effectiveness
ratios and negative case management cost savings (see
table S5, Additional file 1).
Across all transmission settings, the incremental benefits
of booster doses are small and the cost-effectiveness ratios
are higher. Adding mass campaigns has little impact on
overall effect when the primary efficacy is low. However,
for high vaccine efficacy and high coverage, this strategy is
predicted to lead to local elimination of the parasite in
low transmission settings and substantially reduce trans-
mission in medium transmission settings[14] at low addi-
tional costs. Under these conditions, because of the effects
of the vaccine on transmission, delivery via mass cam-
paigns plus EPI becomes a cost-effective alternative to EPI
alone.
Blood-stage vaccines
At the reference transmission intensity, BSV of moderate
efficacy with a price of US$ 2 per dose applied through EPI
achieves a cost per uncomplicated episode averted of
about US$ 9 (see table S1, Additional file 1), which is
higher than for the corresponding PEV, but the costs per
DALY averted (US$ 21) and per death averted (US$ 630)
are lower than for PEV (see table S2, Additional file 1). At
higher efficacy levels, the cost-effectiveness ratios
decrease, following the same patterns as for PEV (Figure
2). Adding booster doses increases the cost-effectiveness
ratios somewhat. Mass campaigns also increase the cost-
effectiveness ratios except for uncomplicated episodes,
where they decrease.
At low transmission intensity BSV averts a lower propor-
tion of uncomplicated and severe cases and deaths than
PEV[14] and the cost effectiveness ratios are higher for all
outcomes. Adding booster doses leads to slightly higher
costs per uncomplicated episode averted (see table S1 and
S3, Additional file 1), and much higher costs per DALY
and death averted (see table S2 and S3, Additional file 1,
and Figure 2). Adding mass campaigns to EPI leads to a
dramatic reduction in the cost per uncomplicated episode
averted, but the costs per DALY and death averted are only
slightly lower (see table S1, S2, S3, Additional file 1, and
Figure 3, 4).
In high transmission settings BSV is more effective than
PEV especially in averting severe and mortality events[14]
and it is also more efficient. Under EPI alone the cost per
uncomplicated episode averted, in the highest transmis-
sion setting, is US$ 3.8, the cost per DALY averted is
US$13.5 and the cost per death averted is US$401, at vac-
cine price US$ 2 per dose (see table S1 and S2, Additional
file 1, and Figure 3). Adding boosters or mass campaigns,
leads to higher incremental costs than incremental bene-
fits (see table S1, S2, S3, Additional file 1, and Figure 2).
Across all transmission settings, the incremental costs of
adding booster doses to EPI are higher than the incremen-
average length of stay when patient dies 2[ 4 1 ]
% of hospital cost that are recurrent 71.1 [35]
% of hospital recurrent costs that are fixed 50.0 [41]
Table 3: Case management unit costs US$ 2006 (Continued)
Table 4: ACT costs
Age Cost/dose in $
(including 12% dist)
Cost per course in $
+ 25% wastage
<3 years – 5 to 14 Kg 1.008 1.260
3–9 years – 15 to 24 Kg 1.568 1.960
10–14 years 25 to 34 Kg 2.128 2.660
15+ years – Above 35 Kg 2.688 3.360
Source: http://www.who.int/malaria/cmc_upload/0/000/015/789/CoA_website5.pdf accessed 15 July 2008.Malaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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tal benefits and this is particularly true for severe episodes,
DALYs, and mortality (see table S1, S2, S3, Additional file
1, and Figure 2). In low transmission settings, campaigns
improve cost-effectiveness for uncomplicated episodes
averted, but do not change cost-effectiveness estimates for
DALYs and deaths averted. However, in moderate to high
transmission settings, the incremental costs of campaigns
are higher than the incremental benefits (see table S1, S2,
S3, Additional file 1, and Figure 2).
Combination vaccines and MSTBV
Combining BSV with PEV (with matched efficacies) in
general, improves or matches the cases averted over PEV
alone for all transmission settings and vaccine delivery
Effect of initial efficacy on cost-effectiveness of PEV by transmission setting and delivery modality* Figure 1
Effect of initial efficacy on cost-effectiveness of PEV by transmission setting and delivery modality*. Results 
obtained assuming a vaccine half-life of 10 years, homogeneity value of 10, and vaccine price of US$2. EPI & Campaigns means 
EPI with 70% mass vaccination. *data for EIR in some cases are not shown in the figure due to a scale problem.
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modalities[14]. The cost-effectiveness ratios for this com-
bination are lower than those of PEV in all transmission
settings particularly for the cost per DALY and per death
averted and in moderate to high transmission settings (see
table S1, S2, S3 in Additional file 1, and Figure 3, 4). Com-
pared to BSV alone, the cost-effectiveness ratios of com-
bining BSV with PEV are lower, though the difference is
smaller than for PEV and in this case it is higher in mod-
erate to lower transmission settings than in high transmis-
sion settings. Adding booster doses to EPI leads to higher
cost-effectiveness ratios across all transmission settings for
this combination – the costs per uncomplicated episode
Effect of initial efficacy on cost-effectiveness of BSV by transmission setting and delivery modality Figure 2
Effect of initial efficacy on cost-effectiveness of BSV by transmission setting and delivery modality. Results 
obtained assuming a vaccine half-life of 10 years, homogeneity value of 10, and vaccine price of US$2. EPI & Campaigns means 
EPI with 70% mass vaccination.
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averted increases by around 19%–23% while those per
DALY and death averted show even larger increases
(around 30%–40%).
Adding mass campaigns in low to moderate settings lead
to incremental uncomplicated episodes averted that are
higher than the incremental costs. However, in terms of
DALYs and deaths averted the benefits exceed the costs
only in the lowest transmission setting, while they are sig-
nificantly lower in the reference and in high transmission
settings. In high transmission settings even the additional
uncomplicated episodes averted are lower than the addi-
tional costs.
Effect of initial efficacy on cost-effectiveness of all vaccines delivered via EPI by transmission setting* Figure 3
Effect of initial efficacy on cost-effectiveness of all vaccines delivered via EPI by transmission setting*. Results 
obtained assuming a vaccine half-life of 10 years and homogeneity value of 10, and vaccine price of US$2. *data for EIR in some 
cases are not shown in the figure due to a scale problem.
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Combinations of MS TBV with PEV or BSV and the triple
combination do not improve the effectiveness of the vac-
cines alone when delivered via EPI or EPI with boost-
ers[14]. However, adding mass campaigns leads to greater
effectiveness in all transmission settings (Figure 4). The
additional benefits of these combination vaccines are
then much higher than the additional costs compared to
delivering the vaccines under EPI alone and to all delivery
modalities of PEV and BSV alone. In the reference trans-
mission setting, for instance, the cost per uncomplicated
episode averted of combining BSV with MSTBV, delivered
via EPI and mass campaigns, is (at a vaccine price of
Effect of initial efficacy on cost-effectiveness of all vaccines delivered via EPI with 70-% mass vaccination by transmission setting* Figure 4
Effect of initial efficacy on cost-effectiveness of all vaccines delivered via EPI with 70-% mass vaccination by 
transmission setting*. Results obtained assuming a vaccine half-life of 10 years and homogeneity value of 10, and vaccine 
price of US$2. *data for EIR in some cases are not shown in the figure due to a scale problem.
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US$2) US$1.8 and US$2.3 for 70% and 50% coverage
(see table S1, Additional file 1), while the cost per DALY
averted is US$20 and US$ 22 for 70% and 50% coverage
(see table S2, Additional file 1). The costs per DALY
averted vary between US$ 12 and US$40 across transmis-
sion settings with the lowest value in the lowest transmis-
sion setting where the greatest improvement to
effectiveness is observed. The very favourable cost-effec-
tiveness ratios in low transmission settings are related to
the case-management cost savings, which may compen-
sate up to more than 50% of the costs of the vaccine inter-
vention (see table S4, Additional file 1).
Effect of delivery modalities
Adding boosters to EPI does not improve effectiveness or
cases averted over EPI alone by very much even at the very
high coverage level modeled, but it does incur additional
costs. This delivery modality does therefore not represent
a cost-effective alternative to EPI alone in any scenario
(see table S1, S2, S3, Additional file 1).
Delivering all vaccines and combinations via population
based campaigns improves the effectiveness at mass vacci-
nation coverage of 50%, especially in low transmission
settings[14]. Depending on the transmission setting and
the vaccine type considered, the incremental costs of
delivering vaccines via population based campaigns can
be lower than the incremental benefits, leading to a signif-
icant reduction in the cost-effectiveness ratios (see table
S1, S2, S3, Additional file 1, and Figure 4). Disseminating
vaccines via population-based campaign in these cases is
predicted to be a more cost-effective way of delivering
malaria vaccines than EPI alone. Increasing the coverage
of the mass vaccination campaigns increases the effective-
ness and cases averted for all vaccine and vaccine combi-
nations under most transmission settings[14]. However,
the incremental benefits of increasing coverage are often
lower than the incremental costs of achieving it (Figure 5).
In some cases, the predictions suggest an optimal cost-
effectiveness ratio at intermediate values for the campaign
coverage. This is not a consequence of non-proportional-
ity of vaccine delivery costs as a function of coverage
(which could be realistic, but not modeled in this study),
but of the indirect effects of the vaccines.
Effect of vaccine price
Although the simulations focus on comparative cost-
effectiveness of different candidate malaria vaccines and
delivery modalities, and not on the sensitivity of cost-
effectiveness ratios to vaccine prices, which are hypotheti-
cal, it is evident that the cost-effectiveness results are
almost directly proportional to the vaccine prices. In fact,
at an assumed vaccine price of US$ 10 per dose, most cost-
effectiveness ratios are between 4 and 7 times higher than
those obtained at US$ 2 per dose (see table S1, S2, S3,
Additional file 1). At a vaccine price of US$ 2 per dose,
most vaccines and delivery modalities simulated present
cost-effectiveness ratios comparable to those of other
malaria interventions[9,10,41-43], while at a vaccine
price of US$ 10 per dose in many of the simulated scenar-
ios the cost-effectiveness ratios are higher.
Discussion
CEA is a method for evaluating the relative efficiency of
alternative interventions and thus can provide important
information for assessing the potential implications of the
numerous malaria vaccine candidates. This study used
stochastic simulations of P. falciparum malaria epidemiol-
ogy, combined with a case management model, to simu-
late the cost-effectiveness of potential malaria vaccines
under various transmission settings and delivered via dif-
ferent modalities. This is an extension of previous research
on pre-erythrocytic vaccines delivered via the EPI[12].
The simulations presented suggest that the cost-effective-
ness of candidate malaria vaccines is likely to differ sub-
stantially according to the transmission intensity and to
the delivery modality adopted. They also suggest that
alternative vaccine delivery modalities to the EPI may
sometimes, but not always, be more cost-effective than
the EPI. In general, at moderate vaccine prices, most vac-
cines and delivery modalities simulated are likely to
present cost-effectiveness ratios, which compare favoura-
bly with those of other malaria interventions [41-43],
making them potential attractive malaria control strate-
gies, from an economic perspective, in malaria endemic
countries.
These simulations have various limitations, as described
in the companion article on the epidemiological
effects[14]. For the economic analysis, one of the most
important limitations is related to the relatively simple
case management model used to assess the impact of
malaria vaccines on the costs to the health system and to
patients. As the case management model used is the same
for all scenarios simulated, the relative cost-effectiveness
of the vaccines modeled, and, therefore, the comparisons,
should only be slightly affected by it. However, further
research and modeling of health system characteristics in
malaria endemic settings is required. Additionally, the
vaccine delivery modalities modeled may not be feasible
to implement in all settings as the coverage and the effec-
tiveness of malaria vaccines is likely to depend strongly on
the characteristics of the health systems where they will be
implemented, including any other malaria intervention
being delivered. For instance, the simulations assumed an
EPI coverage rate of 89%, which is probably higher than
found in some malaria-endemic countries. Lower EPI cov-
erage rates could have an impact on the comparisons
between different delivery modalities.Malaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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Other limitations of this study include that the compari-
sons of malaria vaccines – or of combinations of them-
with different characteristics, are based on the same
assumed vaccine price. In practice, the price might vary
according to the characteristics of the vaccines, in particu-
lar for combinations of vaccines. This might be important
for the result that MSTBV combinations were more effi-
cient than vaccines without MSTBV, especially when
delivered via EPI with mass campaigns.
While modeling the costs of different vaccine delivery
modalities, the fact that vaccine delivery costs might vary
Cost-effectiveness of vaccines given different levels of mass vaccination coverage by transmission setting* Figure 5
Cost-effectiveness of vaccines given different levels of mass vaccination coverage by transmission setting*. 
Results obtained assuming a vaccine half-life of 10 years and homogeneity value of 10, and vaccine price of US$2. *data for EIR 
in some cases are not shown in the figure due to a scale problem.
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as a function of coverage (as it is the case for other inter-
ventions[44,45]) was not taken into account. This aspect
was not considered due to the lack of solid evidence on
vaccine delivery costs by coverage levels, especially for
mass campaigns.
Despite these limitations, the simulations presented pro-
vide interesting information for vaccine developers on the
potentials of different candidate malaria vaccines. Previ-
ous simulation of the cost-effectiveness of PEV[12] sug-
gested that at moderate to low vaccine prices, a vaccine
providing partial protection, and delivered via the EPI,
may be a cost-effective intervention in countries where
malaria is endemic. The simulations presented in this arti-
cle, also show that these types of vaccines are more effec-
tive and cost-effective in low transmission settings, and
that the additional costs of delivering a PEV under other
modalities than the EPI are likely to be higher than the
additional health benefits. The only exception is for the
scenario of mass vaccination (added to routine EPI) in
low transmission and for high vaccine efficacies and high
coverage. In contrast to PEV, BSV are predicted to be more
effective and cost-effective at higher transmission settings
than low transmission.
Combinations of BSV and PEV are predicted to be more
efficient than PEV, in particular in moderate to high trans-
mission settings, but compared to BSV, combinations are
more cost-effective in mostly moderate to low transmis-
sion settings. The cost-effectiveness ratios of the other
delivery modalities simulated are higher than those for
EPI alone in almost all scenarios, with the exception of
adding mass campaigns to EPI in the lowest transmission
setting.
Combinations of MSTBV and PEV or PEV and BSV do not
increase the effectiveness or the cost-effectiveness com-
pared to PEV and BSV alone when delivered through the
EPI (including with the addition of booster doses). How-
ever, when applied with EPI and mass vaccinations, com-
binations with MSTBV provide substantial incremental
health benefits and low incremental costs in all transmis-
sion settings. These combination vaccines are therefore
predicted to be interesting only for the settings where
mass vaccination achieving relatively high coverage rates
would be feasible.
According to these simulations, adding booster doses to
the EPI is unlikely to be a cost-effective alternative to
delivering vaccines via the EPI for any vaccine and trans-
mission setting – i.e. the incremental health benefits are
rather low despite the additional costs.
Mass vaccination improves effectiveness, especially in low
transmission settings, and in some scenario the cost-effec-
tiveness ratios compare favourably with those of deliver-
ing the vaccine via the EPI only – the incremental costs are
lower than the incremental health benefits. However,
increasing the coverage of mass vaccination over 50%,
often leads to incremental costs that exceed the incremen-
tal health benefits. In some scenarios, the lowest cost-
effectiveness ratios are reached at intermediate coverage
rates of campaigns. This result is particularly relevant as it
is due to the indirect effect of the vaccines, and not to the
increasing vaccine delivery costs of achieving high cover-
age rates.
In some of the mass vaccination scenarios the simulations
predict that local elimination of the parasite would be, in
principle, possible. In some of these cases, at moderate
vaccine prices, the simulations also predict that the cost-
effectiveness ratios of achieving local elimination might
be relatively low despite the fact that often the incremen-
tal costs of achieving high vaccine coverage are higher
than the incremental benefits. However, the cost-effective-
ness analyses of these simulations include only part of the
economic implications of malaria elimination.
If local elimination were feasible, it might be desirable to
achieve high vaccine coverage rates even if the incremen-
tal costs are high (compared to the incremental health
benefits) as elimination would bring future benefits, how-
ever to sustain elimination over time, once elimination is
achieved there would be a need for strong surveillance
and case detection, which would incur substantial addi-
tional costs that are not included in our simulations. An
assessment of the economic implications of achieving and
sustaining local elimination is planned in the next stage of
the project.
Conclusion
The simulations presented supports that cost-effectiveness
analyses of candidate malaria vaccines may help guide
policy makers and vaccine developers, by providing addi-
tional evidence that malaria vaccines may be efficient
malaria control interventions. The results also indicate
that the transmission setting and the vaccine delivery
modality adopted are important determinants of the cost-
effectiveness of malaria vaccines. While adding booster
doses to the EPI is not a cost-effective alternative to the
EPI, mass vaccination is predicted to provide substantial
health benefits, in particular in low transmission settings,
at low additional costs making such a delivery mode, in
principle, attractive and feasible, and in some cases lead to
local elimination. Nevertheless, achieving high coverage
rates can lead to substantial incremental costs compared
to the health benefits, while intermediate coverage rates
may be a more efficient use of the resources.
While modeling studies such as this one are useful for
exploring the potential impact of malaria vaccines at early
stages of development, vaccine development and imple-Malaria Journal 2009, 8:127 http://www.malariajournal.com/content/8/1/127
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mentation decisions should be also informed by cost-
effectiveness studies carefully tailored to the settings
where the vaccines are likely to be adopted.
Ultimately, the relative efficiency of malaria vaccines will
depend not only on the characteristics of them but also on
the other malaria control interventions implemented. As
malaria vaccines will eventually be deployed as part of
integrated control strategies, the costs and effects of the
interactions of vaccine programmes with those of other
malaria control interventions should also be evaluated.
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